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In a previous paper (1) the rate of development of immunity after 
injection of pneumococeus vaccine into normal  animals  was studied. 
In addition,  the antigenic function of a vaccine made from the intact 
cell was compared with that derived from a watery extract of the cell 
free  from  formed  elements.  In  each  instance,  a  type-specific im- 
munity was initiated.  With  the vaccine made from  the intact  cell, 
active ~mmunity was demonstrated on the 3rd day after injection and, 
in the case of the filtrate, on the 4th day, in both instances increasing 
on the 5th and 6th days after administration  of the antigen. 
In  the  present  study  we  administered  pneumococcus  vaccine  to 
patients with lobar pneumonia to determine whether a similar state of 
active immunity could be induced during  the course of the infection. 
The  literature  concerned  with  the  experimental  production  of 
pneumococcus  immunity  was  reviewed  in  the  first  report.  The 
attempts to induce active immunity in man during the course of lobar 
pneumonia may now be referred to. 
Lister  (2) injected pneumococcus vaccine intravenously into 40 South Mrican 
natives suffering from lobar pneumonia, and concluded that the disease was favor- 
ably influenced.  One patient  who received an  intravenous  inoculation  of  10 
billion organisms the first dose, 20 billion the second dose and 30 billion the third 
dose, showed agglutinins in his serum 6 days subsequent to the first  injection. 
Other investigators have employed subcutaneous injections of much smaller doses, 
such as 30 to 300 millions of diplococci, with reported lowering of the mortality 
rate  of pneumonia  as compared with  control series.  (Wright  (3), Wynn  (4), 
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Girdwood (5), Lambert (6), French (7), Sutton (8).)  Lister was unable to demon- 
strate agglutln~n.~  in the serum of animals or patients when the dose of vaccine 
was limited to hundreds of millions of cocci.  In only one investigation of sub- 
cutaneous immunization was a study made of the appearance of protective sub- 
stance in the patient's serum after administration of Pneumococcus Types I, II 
and III (Lambert).  The results in this instance showed that protective substance 
appeared only against the type of pneumococcus which corresponded to that 
present in the patient's  sputum.* 
However, it was shown by G. and F. Klemperer (9) that the serum of patients 
after the crisis possessed curative powers in pneumococcus  infection in the rab- 
bit,  and Neufeld (10) demonstrated agglutinins in patients convalescing from 
pneumonia. 
That protective substance appeared in the serum of patients at the time of the 
crisis for the type of organism  which was present in the sputum was demonstrated 
by Dochez (11), Clough (12) and others subsequently. 
It is evident that the appearance of protective substance for the ho- 
mologous type of pneumococcus  may be ascribed to the natural course 
of the disease in recovered patients, and not necessarily to the injec- 
tion of vaccine.  It seemed to us necessary to inject heterologous types 
(i.e.,  types of pneumococci not present in the sputum of the patient) 
and  test for the appearance  of protective substances against these 
types in order to demonstrate that active immunity may be induced 
by injection of vaccine during the course of lobar pneumonia.  Thus, 
if specific protective substances against Pneumococcus Type II appear 
after injection of Type II vaccine in a  patient suffering with Type I 
pneumonia, the initiation of this immunity might then be ascribed 
to the introduction of the vaccine. 
The appearance of protective substances against the type of pneu- 
mococcus found in the patient's sputum following the injection of an 
homologous vaccine could only be ascribed to the vaccine if heterol- 
ogous immunity was previously demonstrated under similar circum- 
stances. 
Another  difficulty encountered is  that  the  serum  of  normal  in- 
dividuals occasionally possesses demonstrable immunity against one 
or more types of pneumococcus (Neufeld and Haendel (13),  Clough 
(14)).  In certain of our patients the blood before injectio  n of vaccine 
* As these tables are unpublished, it is due to the kindness of Dr. Lambert that 
I have been allowed  to inspect them and quote the results. .Aj~v.~  T..  BAXAC~r  569 
contained protective substances against one or two types of pneumo- 
coccus.  These cases were therefore excluded. 
Additional confirmation of the fact that heterologous protective sub- 
stance does not spontaneously occur during the time interval covered 
by our experiments  is obtained by the complete absence of heterol- 
ogous immunity in two patients who were treated with subcutaneous 
immunization and a  much larger group  (14  cases)  treated by  intra- 
dermal injection. 
Methods 
The antigens were prepared as described in the previous paper (1).  A virulent 
Pneumococcus Type I  (or Type II or III) culture was passed through a mouse in 
preparation of the vaccine.  0.2 cc. of the heart's blood obtained from the animal 
immediately  after death was inoculated into a test tube containing  5 cc. of beef- 
infusion broth with 2.5 per cent of human serum.  After 8 hours' incubation,  this 
was used to inoculate 250 cc. of similarly prepared broth.  Incubation was carried 
on for 8 hours.  The culture was  then centrifuged  and the supernatant broth 
poured off.  Care was taken not to loosen the sedimented bacteria at the bottom 
of the centrifuge tube which was now carefully rinsed with normal saline to wash 
off all broth adhering to it.  Normal salt solution was added to dilute the bacteria 
to a  concentration of 10 billion  organisms  to 1 cc. of water.  Sterilization  was 
accomplished by heating the suspension for 1 hour at 60QC.  This constituted the 
serum vaccine.  For preparation of the filtrate the serum vaccine was shaken by 
hand for 10 minutes and centrifuged.  The superuatant fluid was passed through 
a Berkefeld  filter,  bottled and placed in the ice-box.  If sterile  on culture,  tri- 
cresol was added to a concentration of 0.3 per cent. 
The filtrate  was injected intravenously into patients  in  doses of  1 to  7 cc. 
Blood was withdrawn before injection  and daily on the 3rd to the 6th day there- 
after.  An estimation  of protective substance  was made in the usual manner by 
injection of graded doses of virulent culture with 0.2 cc. of serum intraperitoneally 
into mice.  The vaccine described above was injected intravenously in doses of 1 
to 5 billion organisms.  Intradermal injection was made in doses of 1 to 3 billion 
organisms (0.1 to 0.3 cc. of vaccine). 
The test for protective substance was performed  wi~ maximally virulent or- 
ganisms, the culture being generally  fatal in 10  -~ or 10  -~ ce. in 24  to 40 hours. 
Controls (usually 3 to 5 mice for each type) were tested in every experiment.  The 
dilution  of culture employed was generally  0.001 cc., 0.0001 cc. and 0.00001 cc. 
Survival (noted S in tables)  thus indicated protection against 100,000, 10,000 and 
1,000 ~. L. D. (minimal lethal doses), respectively.  In instances in which the cul- 
ture killed in a dilution of 10-~, survival of an injection of 0.001 cc. indicated that 
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The "Before," 3rd,  4th, 5th and 6th day bloods were tested by injecting the 
graded dilutions  of culture plus 0.2 cc. of patient's serum into nine mice for each 
type: I, II and III.  Thus, each experiment  consists of the results  in terms of 
survival (S) or death (number of hours after injection) on approximately 150 mice, 
including  controls.  Since the complete  tabulation of all the experiments  would 
occupy too large a space, the findings are condensed into tables which note the day 
on which protective substance  appeared.  This consisted  of survival of  one to 
three animals  on one day followed by a larger number on succeeding days.  A 
single survival that was not followed on other days by more survivals  was reck- 
oned as probably due to chance variation and not as evidence of passive immunity. 
Illustrative tables of individual  experiments  will be cited in each group. 
RESULTS 
Pneumococcus vaccine was administered  in  all  to 37  patients,  29 
of  whom  had  pneumonia  and  8  had  miscellaneous  diseases.  The 
pneumococcus filtrate  was injected  intravenously in  7  patients,  the 
vaccine of the whole organism was injected intravenously in 15 patients, 
intradermally in 13 patients and subcutaneously in 2 patients. 
In the accompanying table (Table I), the results of the subcutaneous  injection 
of 3 billion organisms of each of the three types, I, II and III, are shown.  The 
patient was a man 35 years old, suffering from lobar pneumonia with Pneumococ- 
cus Type I in the sputum, a sterile blood culture and consolidation of the R. ~r. L. 
and R. L.L.  He was treated on the 5th day of disease. 
It is apparent from Table I  that active immunity which was  passively  trans- 
mitted to mice began on the 3rd day and increased on the 4th,  5th and 5th days 
after injection in the case of Pneumococcus Type I, but was absent in Pneumococ- 
cus Types II and III.  Since recovery in Type I  pneumonia is followed by the 
spontaneous appearance of protective substance  for that type, the presence  of 
mouse survival 9 days after onset of illness for the homologous type of pneumo- 
coccus and the absence of mouse survival in the heterologous types indicate that 
the subcutaneous  injection of pneumococcus vaccine was not effective in inducing 
active immunity as demonstrated by mouse protection during the 6 day period 
of the experiment.  The second  case was a  woman of 33 years who had lobar 
pneumonia,  Pneumococcus Type IV in the sputum, sterile blood culture and con- 
solidation of the L.L.Z..  On the 3rd day of the disease she was given a subcutane- 
ous injection of Pneumococcus II and III, 2.5 billion organisms of each type.  No 
evidence of protective substance was apparent during the 6 clay period after injec- 
tion for Pneumococcus II or III. 
The first case in the group treated by intravenous injection of vaccine (Case 1) 
is that of a man 49 years old who had chronic pulmonary tuberculosis, moderately 
advanced, and an acute serofibrinous pleurisy (which at first simulated pneumonia) ALVAN  L.  BARACH  571 
of 2 days' duration.  He was given 2 billion organisms of each type, I, II and III, 
intravenously. 
As seen in Table II, protective substance was present on 4th, 5th and 6th days 
after injection for Pneumococcus Types II and III, and absent for Pneumococcus 
TABLE  I 
Appearance of Protective  Substance in Patient's Serum after Subcutaneous Injection 
of Pneumococcus Vaccine 
Case 36. 
Survival after injection of  [  Survival after injection of  Survival after injection of 
Pneumecoccus I culture plus  [ Pneumococcus II culture plus  Pneumococcus III culture plus 
Day after  0.2 cc. patient's serum  0.2 cc. patient's serum  0.2 cc. patient's serum 
vaccination 
Before 
3rd 
4th 
5th 
6th 
0.00 
24 
24 
24 
24 
24 
40 
24 
24 
24 
24 
24 
24 
24 
4O 
S 
0.0001 
24 
24 
24 
24 
24 
72 
S 
S 
S 
24 
24 
S 
S 
S 
S 
0.00001 
40 
72 
72 
40 
72 
S 
S 
S 
S 
40 
S 
S 
24 
4O 
S 
0:001 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
0.000 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
72 
0.00001 
24 
24 
24 
24 
4O 
24 
24 
24 
24 
24 
24 
24 
24 
24 
40 
0.001 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
0.0001  0.00001 
24  24 
24  24 
24  24 
24  24 
24  24 
24  24 
24  24 
24  24 
24  24 
24  24 
24  24 
S  24 
24  24 
24  24 
24  24 
Controls  Controls  Controls 
0.00001  }  0.00001  0.00000001  }  40 hrs. 
0.000001  40 hrs.  0.000001  0.000000001 
0.0000001  O.O000001  24 hrs. 
O.O0000001 
0.000000001 
D/agnoe/s.--Lobar  pneumonia,  Pneumococcus  Type  I.  Patient  was  given 
pneumococcus vaccine subcutaneously, 3  billion organisms of each type, I, II 
and HI. 
Type I.  Since the patient was not suffering from pneumonia or pneumococcus 
infection, the appearance of mouse survival leads to the conclusion that an im- 
munity against Pneumococcus Types II and III was produced 4  days after in- 
travenous injection of the corresponding vaccine, although no response was elicited 
in the case of Type I. 572  PNEU~OCOCCUS VACCINE.  II 
The next case cited (Case 4) is that of a man 28 years old who developed a post- 
operative bronchopneumonia involving the ~.L.L. and L.L.T..,  in whose sputum were 
Streptococcus hacmolyticus, staphylococcus and Friedl/inder bacillus, but no pneu- 
mococci.  He was given 4  billion pneumococci, Type II, intravenously on the 
6th day of disease, and 3 days later protective substance appeared in his blood for 
TABLE  II 
Appearance  of Protective Substance in Patient's Serum after Intravenous  Injection 
of Pneumococcus Vaccine 
Case 1. 
Survival after injection of  Survival after injection of  Survival after injection of 
Pneumococcus I culture plus  Pneumecoccus II culture plus  Pneumececcus HI culture plus 
Day after  0.2 cc. patient's serum  0.2 ec. patient's serum  0.2 cc. patient's serum 
vaccination  [ 
Before 
3rd 
4th 
5th 
6th 
0.001 
20 
30 
30 
20 
30 
30 
35 
40 
40 
20 
20 
40 
20 
48 
48 
0.0001  0.00001 
30  30 
30  30 
30  30 
35  30 
32  30 
35  30 
40  40 
40  40 
4O  40 
4O  40 
40  40 
40  48 
48  48 
48  48 
48  48 
0.001 
40 
40 
40 
3O 
3O 
3O 
3O 
3O 
3O 
6O 
6O 
S 
120 
S 
S 
0  ~01 
~0 
S 
S 
S 
S 
S 
S 
S 
0.00001 
4O 
40 
40 
4O 
40 
40 
S 
S 
S 
S 
S 
S 
S 
S 
0.001 
4O 
40 
40 
4O 
40 
40 
4O 
40 
60 
S 
S 
S 
6O 
6O 
40 
0.0001 
40 
40 
40 
40 
40 
40 
60 
80 
S 
40 
S 
S 
40 
6O 
6O 
0.00001 
40 
40 
4O 
4O 
4O 
4O 
4O 
S 
S 
4O 
6O 
S 
S 
S 
S 
Controls  Controls  Controls 
0.00001  ]  0.00001  ]  0.00001  } 40 hrs. 
0.000001  I  40 hrs.  0.000001  I  40 hrs. 
0.0000001  0.0000001 
Diagnosis.--Acute  serofibrinous pleurisy.  Patient  was  given  pneumococcus 
vaccine intravenously, 2 billion organisms of each type, I, II and III. 
Type II (continuing on the 4th, 5th and 6th days) but none developed for Types 
I  and III. 
In  this  case of pneumonia  without  pneumococcus  infection,  immunity  was 
developed specifically  for the type of pneumococcus injected and not for the other 
two types during the febrile period of the disease.  It began 3 days after intra- 
venous injection of the vaccine. 
In the case shown in Table IV (Case 6), the patient was a man 47 years old who ALVAN L. BARACH
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had lobar pneumonia, Pneumococcus Type IV in his sputum, negative blood cul-
tureand consolidation of the R.L.L . He wasgiven 4billion pneumococci of each
Type II andIII in twodoses on the 5th day of disease .
It will be observed that protective substance appeared on the 4th day after
injection for Type II pneumococcus, and increased markedly on the 5th and6th
TABLE III
Appearance of Protective Substance in Patient's Serum after Intravenous Injection
of Pneumococcus Vaccine
Case 4.
Controls
0.00001
0.000001
0.0000001
0.00000001
Diagnosis.-Post-operative bronchopneumonia . Sputum
coccus haemolyticus, staphylococcus and Friedlander bacillus.
billion Pneumococcus Type II intravenously.
40 hrs.
Controls
￿
Controls
0.00001
￿
0.00001
0.000001
￿
~ 40 hrs.
￿
0.000001
￿
40 hrs .
0.0000001
￿
0.0000001
contained Strepto-
Patient received 4
day.
￿
(On the latter day, 0.2 cc . of hisserumprotected against0.01 cc. of culture
with a virulence of 10-9 , approximately 10,000,000 M.L.D .)
￿
In the case of Type
III, protective substanceappeared on the 6th day after injection and was not as
great, (0.2 cc . serum protecting against 0.001 cc . of a culturewith avirulence of
Day after
vaccination
Survival afterinjection of
Pneumococcus I culture plus
0.2 cc . patient's serum
Survival after injection of
Pneumococcus II culture plus
0.2 cc. patient's serum
Survival after injection of
Pneumococcus III culture plus
0.2 cc. patient's serum
0.001 0.0001 0.00001 0.001 0.0001 0.00001 0.001 0.0001 0.00001
Before 24 24 24 24 40 40 24 40 40
40 40 40 40 40 40 24 40 40
40 40 40 40 100 40 40 40 40
3rd 24 24 40 24 100 S 24 40 40
40 40 40 40 S S 24 40 40
40 40 40 40 S S 24 40 40
4th 24 20 24 24 40 40 24 24 24
24 40 40 40 40 S 40 24 24
24 40 40 40 40 S 40 40 40
5th 24 40 40 24 40 S 24 40 40
40 40 40 40 S S 40 40 40
40 40 40 40 S S 40 40 40
6th 24 40 40 24 40 40 24 40 40
24 40 40 24 40 S 24 40 40
24 40 40 40 S S 40 40 40574  vgsuMococcus  VACCINE.  II 
10 -~ or  10,000  M.L.D.).  In this instance, definite heterologous ~mmunity was 
developed during the course of pneumococcus pneumonia. 
The case presented in Table V (Case 12), is a man 40 years old who had lobar 
pneumonia, with Pneumococcus Type I  in the sputum, negative blood culture 
TABLE  IV 
Appearance of Protective Subaance in Patient's Serum after Intravenous Injection 
of Pneumococcus Vaccine 
Case 6. 
Day after 
vaccination 
Before 
3rd 
4th 
5th 
6th 
Survival after injection of Pneumococcus II 
culture plus 0.2 cc, patient's serum 
0.01 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
40 
S 
S 
0.001 
24 
25 
25 
24 
24 
25 
24 
24 
24 
24 
S 
S 
S 
S 
S 
0.0~1 
24 
25 
40 
24 
40 
40 
S 
S 
S 
24 
S 
S 
S 
S 
S 
Survival after  injection  of Pneumococcus 
HI culture plus 0.2 cc. patient's  serum 
0.01 
24 
24 
40 
24 
40 
40 
24 
24 
25 
24 
24 
40 
24 
24 
24 
0.001 
24 
40 
50 
24 
25 
25 
25 
40 
40 
24 
24 
24 
40 
S 
S 
0.0001 
40 
40 
40 
25 
40 
40 
40 
40 
40 
24 
40 
40 
40 
S 
S 
Controls  Controls 
0.0001  24 hrs.  0.0001  24 hrs. 
0.00001  25 hrs.  0.00001  25 hrs. 
0.000001  28 hrs.  0.000001  28 hrs. 
0.0000001  30  hrs.  0.0000001  30  hrs. 
0.00000001  35  hrs. 
0.000000001  40  hrs. 
Diagnosis.--Lobar  pneumonia, Pneumococcus Type IV.  Patient received 4 
billion  organisms of each Type II and III vaccine. 
and consolidation of the R.M.L.  He received 3 billion  pneumococci intravenously 
of each Type I and II on the 3rd day of illness. 
As seen in Table V, protective substance developed for the homologous Type I 
on the 3rd day after injection, and ~gradually increased on the 4th, 5th and 6th 
days; for the heterologous Type II on the 4th day, increasing on the 5th and 6th ALVAN L.  BA.RACH  575 
day after injection.  The blood before injection contained protective substance 
for Type III pneumococcus, with increase in degree on the 3rd to the 6th days 
after injection. 
Tables I  to  V  illustrate the  various  types  of  response  to  intra- 
venous injection of pneumococcus vaccine.  The results in  this  series 
TABLE  V 
Appearance  of Protective Substance in Patient's Serum after Ingrarenous  Injecgon 
of Pneumococcus Vaccine 
Case 12. 
Day after 
vaccination 
Before 
3rd 
4th 
5th 
6th 
Survival  after injection  of 
Pneumococcus  I culture plus 
0.2 cc. patient's  serum 
0.001  .0001  0.00001 
24  24  48 
24  24  48 
48  48  48 
24  24  24 
24  72  S 
S  48  S 
24  24  S 
24  24  S 
48  48  S 
24  48  72 
24  S  48 
24  S  S 
24  S  S 
24  S  S 
24  S  S 
Survival  after injection  of 
Pneumococcus  II culture  plus 
0.2 co. pationt°s  serum 
0.001 
24 
24 
24 
24 
24 
24 
24 
48 
48 
24 
24 
24 
24 
S 
S 
0.0001 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
48 
48 
24 
24 
72 
0.00001 
Survival  after injection  of 
Pneumococcus  nI culture  plul 
0.2 cc. patient's  serum 
24 
24 
24 
24 
24 
24 
48 
48 
S 
24 
S 
S 
72 
S 
S 
0.001  0.0001  0.00001 
24  48  S 
48  48  S 
48  48  S 
24  24  48 
24  S  48 
24  S  S 
24  72  48 
24  48  S 
24  S  S 
24  24  S 
48  48  S 
48  48  S 
24  S  S 
48  S  S 
S  S  S 
Controls  Controls  Controls 
0.00001  24 hrs.  0.00001  48 hrs.  0.00001  48 hrs. 
0.000001  48 hrs.  0.000001  48 hrs.  0.000001  72 hrs. 
0.0000001  48 hrs.  O.0O00001  48 hrs. 
0.00000001  48 hrs.  0.00000001 24 hrs. 
O.OGO000001  48 hrs. 
Diagnosis.--Lobar  pneumonia.  Sputum  contained  Pneumococcus  Type  I. 
Patient was given an intravenous injection of pneumococcus vaccine, 3  b/Ilion 
organisms of each Type I  and II. 
have been divided into a  group in which heterologous  vaccine (i.e., 
composed of organisms of a  different type  than that present  in the 
sputum) w~s administered intravenously (Table VII), and a  group  in 576  PNEU~OCOCCUS  VACCINE.  II 
which homologous vaccine (composed of pneumococci of the same type 
as  that  in  the  sputum)  was  given  (Table  IX). 
TABLE  VI 
Apt~earance of Protective Substance after Intravenous Injection  of Pneumococcus 
Vaccine: Heterologous Type Experiments 
Case No.  Organism  in patient's  sputum  type of pneumococcus Day after injection  on  vaccine  administered  which  protective  sub-  stance appeared 
10 
13 
15 
1 
2 
5 
1 
2 
3 
4 
5 
6 
7 
8 
9 
11 
12 
13 
14 
15 
1 
6 
7 
Pneumococcus II 
Hemolytic streptococci 
Tubercle bacillus 
Pneumococcus III 
Tubercle bacillus 
Pneumococcus IV 
Pneumococcus IV 
Friedlgnder bacillus 
Pneumococcus III 
I 
I 
I 
I 
I 
I 
II 
II 
II 
Pneumococcus IV 
Pneumococcus IV 
Pneumococcus I 
Pneumococcus I 
PneUmococcus  I 
Pneumococcus I 
Pneumococcus I 
Hemolytic streptococci 
Tubercle bacillus 
Pneumococcus IV 
Pneumococcus IV 
II 
II 
II 
II 
II 
II 
II 
II 
II 
II 
II 
III 
III 
III 
6 
4 
6 
Negative 
Negative 
Negative 
4 
3 
5 
3 
6 
4 
4 
6 
3 
3 
4 
3 
4 
S 
4 
6 
6 
Total experiments,  23. 
Total cases showing protective substance 20, or 87 per cent. 
Average day of onset of 3 cases injected with Type I vaccine, 5.3 days. 
Average day of onset of 14 cases injected with Type II vaccine, 4.1 days. 
Average day of onset of 3 cases injected with Type III vaccine, 5.3 days. 
Combined average day of onset of 20 cases injected with Type I, II or III 
vaccine, 4.4 days. 
In the accompanying table  (Table VI), there  were  23  instances in 
which a  heterologous vaccine was given intravenously.  Of these 20, 
or 87  per  cent,  developed  protective  substance  for the organism  in- ALVA~  L.  BA~ACH  577 
jected.  The  average  day  of onset  of  active  immunity  as  demon- 
strated  by passively  transmitted  protection  to  mice  was  4.4  days 
after injection; 4.1 days for 14 cases of Pneumococcus Type II,  and 
5.3  days for 3  cases of Type I  and  3  cases of  Type  III.  Patients 
without pneumococcus infection  were included in this group in order 
to add further evidence that heterologous immunity was due to  the 
TABLE  VII 
Appearance of Protective Substance after Intravenous Injection of Pneumococcus 
Filtrate: Heterologous Type Experiments 
Case No.  Organism in patient's sputum  Ty~ of pneumococcus  DaYwhichafterprotectiveinjectiOnsub.On 
vaccine ~rlmln~tered  stance appeared 
16 
17 
20 
21 
16 
17 
18 
19 
20 
Pneumococcus IV 
Pneumococcus  III 
Pneumococcus IV 
Pneumococcus IV 
Pneumococcus IV 
Pneumococcus III 
Pneumococcus II 
Pneumococcus II 
Pneumococcus IV 
H 
II 
II 
II 
I 
I 
I 
I 
6 
6 
6 
4 
6 
6 
5 
6 
Negative 
Total experiments, 9. 
Total cases showing protective substance, 8, or 89 per cent. 
Average day of onset of protective substance of 4 cases injected with Type II 
vaccine, 5.5 days. 
Average day of onset of protective substance of 4 cases injected with Type I 
vaccine, 5.7 days. 
Combined average day of onset of protective substance of 8 cases injected with 
Types I or II vaccine, 5.6 days. 
introduction  of  vacdne  and  not  to  the  spontaneous appearance of 
pneumococcus protective substance. 
The  results of the intravenous  injection  of pneumococcus filtrate 
have been summarized in two tables, (I) the appearance  of protective 
substance  after administration  of heterologous filtrate  (Table VII), 
and  (2)  appearance  Of protective  substance  after  administration  of 
homologous filtrate (Table VIII). 
In the former table, (Table VII), 9 instances of heterologous filtrate 578  PN~trMOCOCCUS VACCINE.  r~ 
injection  are presented.  In 8,  or 89 per cent,  protective substance 
appeared during the period under observation.  The average day of 
onset of active immunity was 5.6 days after injection; 5£ days for 
Type II filtrate and 5.7 for Type I  filtrate. 
It is of interest  to note that  the intravenous  injection of vaccine 
resulted in the appearance of protective substance 1.2 days earlier than 
the filtrate, being approximately the same difference that was found 
in the animal experiments reported in the previous paper (1). 
TABLE VIII 
Appearar~ce of Protective Substance  after  Intravenous  Injection  of Pneumococcus 
Vaccin~ and Filtrate:  Homologous Type Experiments 
Tivpg_ of pneumococcus  Day after  injection on 
Case No.  Organism in patient's sputum adm~igtered. Vaccine  which  protective  sub- 
or filtrate  stance sppeared 
10 
12 
14 
18 
19 
22 
22 
Pneumococcus II 
Pneumococcus I 
Pneumococcus I 
Pneumococcus II 
Pneumococcus II 
Pneumococcus II 
Pneumococcus I 
Vaccine II 
Vaccine I 
Vaccine I 
Filtrate II 
Filtrate II 
Filtrate II 
Filtrate I 
5 
3 
3 
.3 
6 
4 
4 
Total cases showing protective substanc~ 7~ or 100 per cent. 
Average day of onset of 3 cases injected with vaccine, 3.7 days, 
Average day of onset of 4 cases injected with filtrate, 4.2 days. 
Combined average day of onset of 7 cases injected with vaccine or filtrate~ 4.0 
days. 
In  Table  VIII, the  findings after  intravenous  injection  of homol- 
ogous  vaccine  and  filtrate  are  summarized.  The  average  day  of 
onset  of passively transmitted  ~munity  in  the  case  of 3  vaccine 
cases was 3.7 days, in the 4 filtrate cases, 4.2 days.  In both instances 
immunity  appeared  earlier  than  in  the  corresponding  heterologous 
eases.  That  this might  be due to the spontaneous development  of 
protective  substances  and  not  to  the  vaccine  has  been  previously 
emphasized. 
Two  illustrative  cases  of  intravenous  filtrate  injection  wilt  be 
mentioned. ALVA~  r..  BARACH  579 
TABLE IX 
Appearance of ProScribe Substance after Intravenous I~jeclion  of Antigen Filtrate 
Case  17. 
Survival  after  injection  of  test  culture 
Pneumococcu~  pn~.cus 
~ Typel 
0.001  0,0001  0 00001  0,001  0.0001  0.00001 
Day afWr injc¢~ 
tion~of ~ltratd 
Before 
Ist 
2nd 
~rd 
4th 
5th 
6th 
2 weeks 
2O 
20 
40 
20 
20 
4O 
20 
20 
75 
20 
20 
4O 
20 
2O 
20 
20 
20 
25 
30 
20 
20 
SS 
30 
30 
6O 
20 
25 
40 
20 
20 
40 
25 
40 
40 
20 
20 
40 
20 
20 
25 
25 
24 
40 
24 
20 
96 
25 
4O 
9O 
25 
4O 
70 
20 
40 
40 
24 
4O 
40 
40 
4O 
4O 
40 
4O 
96 
S 
S 
S 
S 
S 
S 
S 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
24 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
Controls  Controls 
20 
20 
20 
20 
20 
40 
40 
40 
S 
20 
25 
25 
24 
20 
2O 
20 
20 
2O 
2O 
2O 
S 
20 
2O 
2O 
2O 
24 
24 
4O 
S 
S 
0.001  2(}  hrs.  0.001  20  hrs. 
0.0001  20  hrs.  0.0001  20  hrs. 
0.00001  25 hrs.  O.QO00!  35  hrs. 
0.000001  40  hrs.  0.000001  40  hrs. 
0.0000001  40 hrs.  0.0000001  40 hrs. 
0.00000001  40 hrs.  0.00000001  40 hrs. 
Di~os~.~Lobar  pneumonia.  Pneumococcus Type III in sputum.  Patient 
received 17 ce. of Pneumococcus I  and II filtrate. 580  PNEUMOCOCCUS  VACCINE.  II 
In the first case (Case 17), a man of 38 years had lobar pneumonia with Pneu- 
mocoecus Type III in the sputum, sterile blood culture and involvement of the 
L.Z~.L.  On the 2rid day of illness, 16 cc. of Pneumococcus Type I  and II filtrate 
were injected intravenously in 5 doses in 24 hours. 
TABLE  X 
Appearance of Protective Substance after Intravenous Injection  of Antigenic Filtrate 
Case  18. 
Survival  after  injection  of  test  culture 
Day after injec-  Pneumococcus  Pneumococcus 
tlon of. filtrate  Type I  Type II 
0.001  0.0001  0.00001  0.001  0.0001  0.00001 
Before 
3rd 
4th 
5th 
6th 
8th 
20 
20 
40 
20 
20 
20 
20 
20 
40 
20 
20 
40 
S 
S 
S 
40 
90 
S 
40 
40 
40S 
20 
40 
40 
40 
40 
40 
40 
40 
90 
S 
S 
S 
S 
S 
S 
40 
40 
40 
20 
20 
40 
20 
40 
40 
40 
S 
S 
40 
S 
S 
40 
S 
S 
20 
20 
20 
20 
20 
20 
20 
40 
40 
20 
20 
40 
20 
20 
S 
S 
S 
S 
20 
20 
20 
20 
20 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
20 
20 
30 
20 
20 
20 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
Controls  Controls 
0.000001  )  0.000001  } 
0.0000001  40 hrs.  0.0000001  40 hrs. 
0.00000001  0.00000001 
0.000000001 
Diagnosis.--Lobar  pneumonia.  Sputum  contained  Pneumoeoccus  Type  II. 
Patient received intravenously 17 cc. of Pneumococcus I and II filtrate in 5 doses. 
As seen in Table IX, protective substances appeared on the 6th day (and were 
still present on the 14th day) after injection against Pneumococcus Types I  and 
II.  In this instance of immunity induced against two heterologous types of pneu- 
mococcus, the filtrate appeared clearly to be the cause of the appearance of pro- 
tective substance. ALVAN  L.  BAI~ACH  581 
The second case (Case 18), was a  woman 28 years old who  had  lobar pneu- 
monia, with Pneumococcus Type II in sputum, sterile blood culture and consoli- 
dation of the R.L.L.  On the 5th day of disease, 17 ec. of Pneumococcus Type I 
and II filtrate were injected intravenously in 5 doses. 
TABLE  XI 
Appearance ~  Protective Substance aflerlntrad~mal  I~ection~ Pneumococc~ 
V~c~e 
Het~ologous.C~ 
Case No. 
23 
24 
29 
23 
29 
26 
27 
25 
28 
34 
33 
32 
32 
33 
33 
34 
34 
35 
24 
27 
25 
26 
27 
35 
Org~  in patient's  sputum 
Pneumococcus  I 
Pneumococcus  I 
Pneumococcus  I 
Pneumococcus  I 
Pneumococcus  I 
l~neumococcus IV 
Pneumococcus  IV 
Pneumococcus  IV 
Tubercle bacillus 
Pneumococcus III 
Pneumococcus  I 
Pneumococcus  IV 
Pneumococcus  IV 
Pneumococcus  IV 
Pneumococcus  IV 
Pneumococcus  HI 
Type of pneumococcus 
administered 
II 
II 
II 
III 
II 
III 
II 
II 
IIl 
III 
II 
II 
II 
I 
II 
I 
II 
III 
II 
III 
III 
I 
I 
Day after injection on 
which protective sub- 
stance appeared 
5 
6 
4 
3 
4 
4 
5 
5 
5 
4 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
10 of 24 cases, or 42 per cent, developed protective substance after intradermal 
vaccination.  Average day of onset, 4.5 days after injection. 
As noted in Table X, protective substances appeared on the 3rd day after injec- 
tion in the case of the homologous Type II filtrate and 5 days after injection in the 
heterologous Type I filtrate. 582  PNEU~OCOCCUS  VACCINE.  II 
The  results  of  the  intradermal  injection  of  vaccine  may  now  be 
summarized. 
Of  24  instances  in  which  heterologous  pneumococcus  vaccine was 
injected intradermally, 10, or 42 per cent, showed  a  positive response, 
TABLE  XII 
Appearance of Protective Substance in Patient's Serum after Intradermal lnjection 
of Pneumococcus Vaccine 
Case 27. 
Day after  Survival  after injection  of  Pneumococcus  I culture plus 
0.2 cc. patient's serum  vaEclnation I 
.!  0.001  0.0001  0.00001 
Before 
3rd 
4th 
5th 
6th 
40  40  40 
40  40  4O 
40  4O 
20  40  40 
40  40  4O 
40  4O 
20  20  40 
20  40  40 
40  40 
40  40  40 
40  40  40 
40  40 
48  48  48 
45  48  48 
6O  48 
Survival after injection of  Survival after injection  of 
Pneumococcus  II culture plus  Pneumococcus  III culture plus 
0.2 co. patient's serum  0.2 co. patient's serum 
o.o0ol 
40 
40 
40 
20 
4O 
40 
20 
20 
40 
40 
40 
40 
20 
40 
40 
0.00001 
20 
4O 
40 
20 
40 
40 
90 
4O 
40 
20 
20 
40 
4O 
60 
6O 
0.001 
20 
40 
40 
40 
40 
40 
40 
40 
40 
4O 
4O 
0.0001 
40 
4O 
4O 
20 
40 
40 
40 
4O 
40 
40 
40 
S 
40 
S 
S 
0.001 
20 
4O 
20 
20 
20 
20 
20 
4O 
20 
20 
I 0.00001 
40 
4O 
40 
40 
40 
40 
40 
80 
40 
40 
40 
40 
40 
80 
Controls  Controls  Controls 
0.00001  20 hrs.  0.000001  40 hrs.  0.00001  40 hrs. 
0.000001  25 hrs.  0.0000001  40 hrs.  0.000001  40 hrs. 
0.0000001  30 hrs.  0.00000001  40 hrs.  0.0000001  40 hrs. 
0.00000001  40 hrs.  0.000000001 80 hrs.  0.00000001 40 hrs. 
0.000000001  45 hm. 
Diagnosis.mLobar  pneumonia.  Sputum  contained  Pneumococcus  Type IV. 
Patient received an intradermal injection of pneumococcus vaccine, 2 billions of 
organisms of each Type I, II and IH. 
and had an  average day of onset of immunity  of 4.5 days  after injec- 
tion.  The  degree of  immunity  as well  as  its  regularity is much less 
marked  than  in intravenous  injection.  One illustrative case of this 
group will be cited: ALVAN L. BARACH  583 
The patient (Case 27) was a man 38 years old who had lobar pneumonia, with 
Pneumocdccns Type IV in the sputum, negative blood cultures and consolidation 
of the ~,L.L,  He was given an intradermal injection of 2 billion pneumococci  of 
each Type I, II and III on the 3rd day of disease. 
As will be seen in Table XII, no immunity appeared for Pneumococcus Types 
I and II, but one survival was present for Type III 5 days after injection and two 
survivals 6 days after injection.  A slight though definite instance of heterologous 
pneumococcus immunity seemed to result from intradennal vaccination. 
DISCUSSION 
Inasmuch  as  pneumonia  is  a  self-llmited  disease  ending  with 
recovery or death,  generally between the  7th and  12th  days  after 
onset, 3 to 5 days are frequently afforded in which an attempt can be 
made to produce active immunity before the natural termination of 
the disease takes place.  The previous study of the  rate of develop- 
ment of pneumococcus immunity  in animals was suggested by Dochez 
(11) in order to determine whether active immunity to the pneumo- 
coccus could be developed in a sufficiently short space of time as to 
make the injection of vaccine a  therapeutic measure in lobar pneu- 
monia.  In addition, the life of the pneumonia patient, in the author's 
experience  (15),  was  at  times  prolonged  by  oxygen  treatment,  a 
circumstance  that  seemed  to  increase  the  possibilities  of  vaccine 
treatment in an individual case. 
That a rational basis for applying vaccine therapy in lobar pneu- 
monia is now present has been recently emphasized by Zinsser (16). 
He states that autolmmunization from the patient's own lesion may 
be inefficient for two reasons:  (1)  the fact that considerable autolysis 
of the pneumococcus takes place in the lung (17), and (2) that auto- 
lyzed pneumococd possess little antigenic value, and are especially 
deficient in the capacity to evoke type-specific antibodies (18).  Since 
active immunity in animals within a 3 to S day period was produced in 
the study above referred to,  and  similar results were reported by 
Goodner (19) at the same time, a rational basis for attempting vaccine 
therapy in lobar pneumonia seemed justified. 
It may also be noted in this connection that the site of the antibody- 
producing tissues is  thought to be in the  capiUary and lymphatic 
endothelium  and  other  reficulo-endothdial  cells  (Boone  (20)  and 
Manwaring (21)),  The presence of large numbers of partially auto- 584  PNEUMOCOCCUS  VACCINE.  II 
lyzed pneumococd  in the lung which escape in relatively small numbers 
into the blood stream might therefore provide a less efficient stimulus 
for the production of protective antibodies than the introduction into 
the vascular system of large numbers of whole dead pneumococcus 
organisms. 
The intravenous injection of pneumococcus  vaccine in human beings 
was followed by the appearance of specific protective substances in 
their  serum  4  to  5  days  after  administration.  This  was  demon- 
strated in cases of miscellaneous disease without lung involvement, in 
pulmonary inflammation without pneumococcus  infection and in lobar 
TABLE  XIII 
Temperature Range on Day Protective Substance Appeared after Intravenous Injec- 
tion of Pneumococcus Vaccine 
Case No.  Temperature range 
1 
4 
10 
12 
13 
3 
6 
7 
8 
9 
11 
14 
100.8-103.8  ° 
100.0-103.0  ° 
100.4--102.0  ° 
101.0-103.0  ° 
100.2-104.0  ° 
98.2-  99.8  ° 
98.2-  99.2  ° 
98.8-  99.4  ° 
98.6-  99.6  ° 
99.6-104.0  ° 
98.0-  99.2  ° 
99.4-100.5  ° 
pneumonia caused by the pneumococcus.  By the injection of heterol- 
ogous types of pneumococcus, it was possible to evoke specific pro- 
tective substance for the corresponding types during the febrile course 
of pneumonia.  In this discussion, emphasis has been placed on the 
development  of specific protective substance during the course of acute 
pneumonia.  Although all patients were injected in the presence of 
fever, in many instances the temperature had declined to normal or 
nearly so when antibodies appeared in the serum.  It was possible, 
however, to  demonstrate the production of specific protective sub- 
stance during the febrile period.  In two cases of intravenous filtrate 
injection and five cases of intravenous vaccine injection, antibodies ALV~ L.  BARACE  585 
were present in the serum while the acute febrile stage of the pneu- 
monia was in progress.  A  table  (Table XIII)  of the  temperature 
range in  the  cases  who were given intravenous vaccine shows  the 
degree of fever on the day when protective substances first appeared. 
The  first  five  developed  antibodies  while  definite  fever was  still 
present.  The remainder were in  a  nearly afebrile  condition when 
protective antibodies were demonstrated.  No  case was  considered 
as belonging to the febrile group if the temperature at any time went 
below 100  ° .  It seems evident, therefore, that active immunity may 
be induced during the febrile course of pneumonia as a result of intra- 
venous injection of pneumococcus vaccine. 
The appearance of protective substance after injection of homol- 
ogous vaccine appeared almost a day earlier than that which followed 
heterologous vaccine, but it is not possible to affirm that the injection 
of the vaccine in an individual instance was responsible for the appear- 
ance of homologous protective substance.  Our experiments indicate, 
however, that immunity  may generally be established 4 to 5 days after 
intravenous injection of pneumococcus vaccine.  In cases of pneu- 
monia that are seen early in the disease,  the capacity to evoke type- 
specific protective substances in 4 or 5 days may make this procedure 
of therapeutic value. 
Subcutaneous injection of vaccine in two cases of pneumonia and 
in ten normal donors*  did not produce protective  substance within 
this  period.  In  Whitmore's  (22) experiments with  pneumococcus 
vaccine injected subcutaneously in normal human beings,  protective 
substances did not appear in the serum until  8 days after injection. 
The same result was reported by Cecil and Austin (23).  The results 
of Lambert in his own series (referred to in the early part of the paper) 
showed no  heterologous protection.  Although clinically a  lowered 
mortality was present in the treated group of Lambert, the factor 
responsible for the favorable result does not appear in immunological 
studies so far reported. 
It must be remembered, however, that  the object of injection of 
vaccine is to produce active immunity, and that the measurement of 
protective substance in the serum of the patients records only trans- 
* The findings  on donors  is part of a separate report on immune  transfusion. 586  PNEUMOCOCCUS  VACCINE.  II 
retable or passive immunity.  A state of active immunity against the 
pneumococcus may be produced without giving evidence of its exist- 
ence by the presence of protective antibodies in the serum.  This has 
been  demonstrated by  several  workers,  particularly  by  Cecil  and 
Steffen (24), who were able to immunize monkeys against pneumonia 
by three subcutaneous injections of pneumococcus vaccine at weekly 
intervals.  Numerous instances occurred in which the monkeys sur- 
vived lethal doses of virulent cultures without possessing either serum 
agglutinins  or  protective  substance.  Active  immunity,  however, 
was not produced within the first 6 days after subcutaneous injection 
of vaccine.  Immunization of rabbits with Type III pneumococcus 
may also be effective in producing active immunity against infection 
in  the absence of type-specific protective  antibodies  (Tillett  (25)). 
The  results  of  intradermal  injection  of  vaccine  are  confusing. 
Although the majority of cases were negative, apparent instances of 
induction of active immunity did occur.  The degree and regularity 
of response in an individual case was much less marked than in the case 
of intravenous injection of vaccine.  The findings were sufficiently 
indefinite as to permit no conclusion as to the effect of the intradermal 
injection of vaccine in the production of pneumococcus immunity. 
The clinical results have not been emphasized in this series, since 
the production of heterologous protective substance seemed necessary 
to demonstrate that an  immunity may actually be initiated during 
the febrile period of pneumonia by the intravenous injection of a suit. 
able pneumococcus antigen.  There were 20 cases of pneumonia, 17 
lobar pneumonia and 3  bronchopneumonia, who received an intra- 
venous injection of pneumococcus vaccine or filtrate.  Of  these,  2 
died.  One was a patient who had a  Pneumococcus Type IV in the 
sputum with a  persistent Type IV pneumococcus bacteremia.  She 
received an intravenous injection  of Pneumococcus Type I  and II 
filtrate.  The other death occurred in a patient who had a lobar pneu- 
monia due to Pneumococcus Type II with  a  blood stream infection 
with Pneumococcus Type II.  The patient was injected with  Pneu- 
mococcus Type I  and II vaccine intravenously.  Of 9 patients with 
pneumonia, 7 lobar and 2 bronchopneumonia, who received an intra- 
dermal injection of vaccine, 1  died.  Two patients who received a 
subcutaneous  injection of vaccine  recovered.  Eight  patients  with ,~v.~  L.  BA~AC~  587 
miscellaneous disease were treated, of whom one subsequently died of 
causes unrelated to vaccine injection.  Four cases were entirely ex- 
cluded because they died before observations on  the appearance of 
protective substance could be made.  Their clinical course gave no 
indication of having been in any way affected by the introduction of 
vaccine. 
TABLE  XIV 
Clinical Data on Pneumonia  Patients Who Received an  Intravenous  Injection of 
Pneumococcus Antigen 
Case 
No. 
5 
6 
7 
8 
9 
I0 
11 
12 
13 
14 
16 
17 
18 
19 
20 
21 
22 
Diagnosis 
Lobar pneumonia 
Lobar pneumonia 
Lobar Pneumonia 
Lobar paeumonia 
Lobar pneumonia 
lobar pneumonia 
Lobar pneumonia 
lobar pneumotfia 
Lobar pneumonia 
Lob~ pneumonia 
Lobar pneumonia 
Lobar pneumonia 
Lobar p~umc~a 
Lobar pneamonia 
Lobar pneumonia 
Lobar pneumonia 
lobar pneumonia 
Bronchopneumonia 
Bronchopneumonia 
Bronchopneumonia 
Day of 
Organism  in tputum  disease 
injected 
Pneumococcus III  3 
Pneumococcus IV  5 
Pneumococcus IV  4 
Pneumococcus i  3 
Pneumococcus i  2 
Pneumococcus II  5 
Pneumococcus I  2 
Pneumococcus I  3 
--  7 
Pneumococcus I  6 
Pneumococcus IV  1 
PneumococcuS IiI  2 
l>neumoco~cu~  II  5 
Pn~amococcus II  3 
Pneumococcus II  4 
Pneumococcus IV  1 
Pneumococcus I, II  4 
b 
Pneumococcus W  3 
Streptococcus  6 
/u~ntd:~/.u,, 
Friedliinder badL 
ins 
4 
Pneumococcut  Out- 
antigen  employed  come 
Vaccine I, II  S 
Vaccine II, III  S 
Vaccine II, III  S 
Vaccine  I  S 
Vaccine II  S 
Vaccine I, II  D 
Vaccine II, iIi  S 
Vaccine I, ii  S 
Vaccine I, II  S 
Vaccine I, II  s 
F'fltrate I, II  S 
Filtrate I, II  S 
Filtrate I, II  S 
Filtrate t, II  S 
Filtrate I~ II  S 
Filtrate I, II  D 
Filtrate I, II  S 
Vaccine I, II 
Vacc~me I, Ii 
Vaccine II 
None of the patients who received an intravenous or iatradermal 
injection of pneumococcus vaccine experienced any reaction  There 
was no change in pulse, respiration or temperature.  No  consistent 
alteration of the clinical course of the disease was discerned.  The 
pneumococcus filtrate was administered intravenously 28  times to 7 588  PNEUMOCOCCUS  VACCINE.  II 
patients and in only one instance did a foreign protein reaction occur. 
In this case, a  chill of moderate severity was followed by a deferves- 
cence of fever in 8 hours with a return of the temperature to its previous 
level 12 hours later. 
The  number  of  cases  of pneumonia treated  by  the  intravenous 
injection of homologous pneumococcus vaccine is too small to permit 
conclusions as to its therapeutic value at this time. 
SUM~4~RY 
1.  Pneumococcus vaccine  was  administered  to  29  patients  with 
pneumonia to  determine whether a  state of immunity could be in- 
duced during the course of the disease.  Twenty patients  received 
an intravenous injection of pneumococcus vaccine or pneumococcus 
filtrate.  Nine pneumonia patients received an intradermaI injection 
of vaccine.  Eight  patients  with miscellaneous disease  received an 
intravenous or intradermal injection of pneumococcus vaccine. 
2.  Of 23 tests in which the serum of the patient was studied for the 
appearance  of  protective  substance  after  intravenous  injection  of 
heterologous pneumococcus vaccine,  20  or  87  per  cent  showed  a 
positive response within 6 days after the administration of the anti- 
gen.  The average day of onset was 4.4 days after injection. 
3.  Of  9  tests  of  the  same  character  following  the  intravenous 
injection of pneumococcus filtrate, 8 or 89 per cent showed a positive 
response.  The average day of onset of protective substance was 5.6 
days after injection. 
4.  The appearance of specific protective substance following heter- 
ologous injection of pneumococcus vaccine appeared to be due to the 
introduction  of  the  vaccine  and  not  to  the  natural  course  of the 
disease, as was shown by negative control experiments. 
5.  Of 24 tests with intradermal injection of vaccine, 10 or 42  per 
cent  developed  slight  protective  substance  of  irregular  degree  4.5 
days after injection. 
6.  No immediate reactions were observed following the intravenous 
or intraderma] injection of pneumococcus vaccine.  One chill occurred 
after  injection  of  pneumococcus filtrate.  Of  20  cases  with  intra- 
venous injection of pneumococcus vaccine or filtrate, 2 died of their 
disease, one a case in which homologous vaccine was used and one in 
which heterologous vaccine was administered. ALVAN L.  BARACH  589 
7.  Conclusions concerning the therapeutic value of the introduction 
of pneumococcus vaccine in pneumonia must await further investiga- 
tion.  These studies demonstrate that specific protective substances 
generally appear 4  to 5  days after intravenous injection of pneumo- 
coccus vaccine during the course of lobar or bronchopneumonia. 
The author takes pleasure in expressing his sincere appreciation for 
the aid which he received from Dr. Alphonse Dochez during the course 
of this work. 
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